Publications by authors named "Alexander Vorog"

Claim this Profile
P
Population Pharmacokinetic and Exposure-Response Analyses for Ponatinib in the Phase 3 PhALLCON Study.
Michael J Hanley, Thomas R Larson, Paul M Diderichsen, Anna Largajolli, Katrina Hui, Alexander Vorog

Clin Transl Sci· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Alexander Vorog

Leukemia· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Elias Jabbour, Hagop M Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica T Leonard, Alexander Vorog

JAMA· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials.
Elias Jabbour, Jane Apperley, Jorge Cortes, Delphine Rea, Michael Deininger, Alexander Vorog

Leukemia· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response-Based Dosing for Ponatinib: Model-Based Analyses of the Dose-Ranging OPTIC Study.
Michael J Hanley, Paul Diderichsen, Benjamin Rich, Anna Largajolli, Emilie Schindler, Alexander Vorog

Clin Pharmacol Ther· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib Versus Placebo as Postinduction Maintenance Therapy in Newly Diagnosed Multiple Myeloma Patients: An Analysis by Age and Frailty Status of the TOURMALINE-MM4 Study.
Sara Bringhen, Luděk Pour, Reuben Benjamin, Sebastian Grosicki, Chang-Ki Min, Alexander Vorog

Clin Lymphoma Myeloma Leuk· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials.
Bruno Paiva, Irene Manrique, Meletios A Dimopoulos, Francesca Gay, Chang-Ki Min, Alexander Vorog

Blood· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.
Wee-Joo Chng, Sagar Lonial, Gareth J Morgan, Shinsuke Iida, Philippe Moreau, Alexander Vorog

Blood Cancer J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial.
Meletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Alexander Vorog

Blood Cancer J· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial.
Meletios A Dimopoulos, Ivan Špička, Hang Quach, Albert Oriol, Roman Hájek, Alexander Vorog

J Clin Oncol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus infection and chronic myeloid leukemia.
Moosa Patel, Vinitha Philip, Fatima Fazel, Atul Lakha, Alexander Vorog

Leuk Res· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis